+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prescription of hormone replacement therapy in postmenopausal women with renal failure

Prescription of hormone replacement therapy in postmenopausal women with renal failure

Kidney International 56(6): 2243-2247

Prescription of hormone replacement therapy in postmenopausal women with renal failure. Although patients with end-stage renal disease (ESRD) are at increased risk for early menopause, osteoporosis, cognitive dysfunction, and cardiovascular disease, few postmenopausal women are prescribed hormone replacement therapy (HRT). The reasons for the low prescription rate are not known. This study uses data from the United States Renal Data System (USRDS) to assess the prevalence and predictors of HRT use in postmenopausal women with ESRD. Data were obtained from the USRDS Dialysis Morbidity and Mortality Study Wave 2. All women who were at least 45 years of age were considered postmenopausal and were selected for our analysis. Demographics, behavior and medical characteristics were abstracted from the database. Logistic regression was used to estimate the independent contribution of population characteristics in predicting the use of HRT. Linear regression models were used to estimate the relationship between HRT use and both triglycerides and total cholesterol. The overall prevalence of HRT prescription was 10.8%. Important predictors of HRT use included age (aOR = 0.74, 95% CI 0.13 to 0.88, P < 0.001), black ethnicity (aOR = 0.50, 95% CI, 0.31 to 0.78, P < 0.002), college education (aOR = 3. 00, 95% CI, 1.70 to 5.24, P < 0.001), and the ability to ambulate (aOR = 1.99, 95% CI, 1.01 to 3.91, P = 0.05). Serum triglyceride and total cholesterol levels were higher among women treated with HRT than among those not treated with HRT (264 +/- 155 vs. 217 +/- 159 mg/dl, P = 0.001 and 220 +/- 62 vs. 209 +/- 55 mg/dl, P = 0.02, respectively). HRT is prescribed less frequently in postmenopausal ESRD patients than in the general population. Younger age, higher education levels, white race, and the ability to ambulate were important predictors of HRT use. Targeting populations of patients who are likely to benefit from but less likely to be prescribed HRT may increase the prescription of HRT.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 011189958

Download citation: RISBibTeXText

PMID: 10594801

DOI: 10.1046/j.1523-1755.1999.00793.x

Related references

Does hormone replacement therapy affect the use of prescription medicines in postmenopausal women: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757. Bjog 114(5): 548-554, 2007

Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. Journal of Cardiovascular Medicine 10(1): 85-92, 2009

Hormone replacement therapy in postmenopausal women with end-stage renal disease (1). Kidney International 57(1): 341-342, 2000

Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women. Life Sciences 72(11): 1279-1288, January 31, 2003

Hormone replacement therapy in postmenopausal women with end-stage renal disease: a review of the issues. Seminars in Dialysis 14(3): 146-149, 2001

A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric symptoms. Maturitas 44(1): 55-62, January 30, 2003

The effect of hormone replacement therapy on arterial structure and renal function in hypertensive postmenopausal women. American Journal of Hypertension 14(4 Part 2): 125A, April, 2001

Silent onset of postmenopausal endometriosis in a woman with renal failure in hormone replacement therapy: a case report. Journal of Medical Case Reports 4: 248, 2010

Study of tumor S-phase in postmenopausal women diagnosed with breast cancer while using hormone replacement therapy vs those never having used hormone replacement therapy. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 203, 1996

Hormone replacement therapy, renal function and heart ultrasonographic parameters in postmenopausal women: an observational study. International Journal of Clinical Practice 69(6): 632-637, 2016

Effect of hormone replacement therapy on the activities of factor VII and protein C in postmenopausal women women The postmenopausal estrogen/progestin intervention trial. Blood 86(10 SUPPL 1): 200A, 1995

Hormone replacement Up-to-date. Menopause in women and hormone replacement therapy (HRT). Indications for HRT in postmenopausal women. Clinical Calcium 17(9): 1315-1324, 2007

Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Archives of Internal Medicine 160(14): 2161-2166, 2000

Hormone replacement therapy does not prevent coronary heart disease and is associated with increased overall risk for health of postmenopausal women. Final results of studies on hormone replacement therapy efficacy in frame of Women's Health Initiative and data from other recent studies. Kardiologiia 43(9): 77-79, 2004